The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Big Data, Real World, Multi-State Study Finds RSV Vaccine Highly Effective in Protecting Older Adults Against Severe Disease, Hospitalization and Death Oct. 17, 2024 — This multi-state study is ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...

while some current vaccines are only modestly effective against their target germ, like the seasonal flu shot. There’s only so much time and resources that can be devoted to developing vaccines ...

The Centers for Disease Control and Prevention now recommends that people ages 65 and up and those with weakened immune ...

Kennedy Jr. is part of President-elect Donald Trump‘s transition team, how should investors think about his potential ...

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

LILLE, France, Nov. 12, 2024 /PRNewswire/ -- Today Vaxinano, a biotech company headquartered in Lille (France) announced an ...

New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology platform trigger targeted immune responses Results also showcase the successful design of a proprietary pref ...